Neoadjuvant Pyrotinib Versus Placebo Combined With Chemotherapy in HR-positive and HER2-low Early Breast Cancer
Conditions: Breast Cancer Invasive; Hormone-receptor-positive Breast Cancer; HER2 Low Breast Carcinoma; Early-stage Breast Cancer Interventions: Drug: Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel; Drug: Placebo, epirubicin or doxorubicin, cyclophosphamide, paclitaxel Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | HER2 | Hormones | Hospitals | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Research